AbbVie Inc. $ABBV Shares Sold by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC lessened its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 4.7% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,204,834 shares of the company’s stock after selling 58,806 shares during the quarter. Commonwealth Equity Services LLC owned 0.07% of AbbVie worth $223,641,000 as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of the company. HORAN Wealth LLC acquired a new stake in AbbVie in the second quarter valued at approximately $2,977,000. SouthState Corp grew its position in AbbVie by 0.6% in the second quarter. SouthState Corp now owns 78,093 shares of the company’s stock valued at $14,496,000 after acquiring an additional 451 shares in the last quarter. Andra AP fonden grew its position in AbbVie by 3.3% in the second quarter. Andra AP fonden now owns 74,800 shares of the company’s stock valued at $13,884,000 after acquiring an additional 2,400 shares in the last quarter. Horan Securities Inc. grew its position in AbbVie by 3.8% in the second quarter. Horan Securities Inc. now owns 3,989 shares of the company’s stock valued at $740,000 after acquiring an additional 147 shares in the last quarter. Finally, Ethos Financial Group LLC grew its position in AbbVie by 3.4% in the second quarter. Ethos Financial Group LLC now owns 11,693 shares of the company’s stock valued at $2,170,000 after acquiring an additional 387 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Performance

Shares of ABBV opened at $216.96 on Thursday. The business’s fifty day moving average price is $222.84 and its 200 day moving average price is $201.84. AbbVie Inc. has a 12-month low of $163.81 and a 12-month high of $244.81. The stock has a market capitalization of $383.27 billion, a PE ratio of 103.31, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.74 and a quick ratio of 0.61.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The firm had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same period last year, the business posted $3.00 earnings per share. The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.2%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is 524.24%.

Analysts Set New Price Targets

Several analysts have issued reports on ABBV shares. Daiwa Capital Markets raised shares of AbbVie from a “neutral” rating to an “outperform” rating and set a $214.00 price objective for the company in a research report on Thursday, August 7th. Morgan Stanley increased their price objective on shares of AbbVie from $250.00 to $255.00 and gave the company an “overweight” rating in a research report on Friday, August 1st. Guggenheim increased their price objective on shares of AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research report on Monday, October 20th. DZ Bank downgraded shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective for the company. in a research report on Tuesday. Finally, Daiwa America upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and an average target price of $238.05.

Insider Transactions at AbbVie

In related news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the transaction, the executive vice president directly owned 177,292 shares in the company, valued at $35,178,278.64. This trade represents a 19.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.25% of the stock is owned by company insiders.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.